Xcout IntelSign inSubscribe

AcroCyte Therapeutics

BiotechnologyUnited States

AcroCyte Therapeutics, Inc. is a biotechnology company dedicated to overcoming common laboratory challenges through its proprietary R³CE rapid, reproducible, rare cell 3D expansion technology. Recognized with awards such as the Taiwan National Innovation Award, the company focuses on advancing biomedical research and cell-based applications.

Subscribe to see AcroCyte Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

AcroCyte Therapeutics at a glance

AcroCyte Therapeutics is a biotechnology company headquartered in United States. Its most recent funding round, Grant, closed in July 2026. Xcout tracks 5 named people at AcroCyte Therapeutics, including Ying C. Chang, PhD (Chief Executive Officer and Board Member).

Industry
Biotechnology
Headquarters
United States

AcroCyte Therapeutics leadership

  • Ying C. Chang, PhDChief Executive Officer and Board Member
  • Yao-Ting Wang, PhDChairman
  • Ying C. Chang, PhDCo-Founder and Chief Executive Officer
  • Jun-Ji LinBoard Member
  • Ryan ShenBoard Member

AcroCyte Therapeutics funding rounds

Every round on record:

DateRoundAmountInvestors
GrantUndisclosed2 named

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Investors

AcroCyte Therapeutics competitors

A few of AcroCyte Therapeutics's closest competitors — see the full list of competitors and alternatives →

International Stem Cell CORPISCO · BiotechSan Diego, United States
63% matchPublic

International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system. Beyond therapeutics, the company also develops, manufactures, and commercializes anti-aging skincare products and an extensive range of human cell culture products. Its diverse portfolio of human cell culture products serves as vital research tools across numerous scientific disciplines. This includes specialized cells and reagents designed for studying: Dermatology: Skin diseases, toxicology, and wound healing. Cardiovascular & Oncology: Heart and blood vessel conditions, and various cancers. Respiratory: Bronchial and tracheal conditions, toxicity, cystic fibrosis, asthma, and pathogenesis. Reproductive & Urological: Prostate, renal, bladder, corneal, and female reproductive system diseases, as well as general cellular physiology. Musculoskeletal & Metabolic: Skeletal muscle biology, diabetes, insulin pathways, muscle repair, and myotube development. The company also provides adult stem cells for regenerative medicine research and a full complement of reagents and supplements essential for cell growth, staining, and cryopreservation. Distribution of ISCO's skincare range occurs via its website and specialized professional channels, while its human cell culture products reach customers through a dedicated sales force, original equipment manufacturer (OEM) partners, and authorized brand distributors. Established in 2001, International Stem Cell Corporation maintains its headquarters in San Diego, California.

Market cap$2.3M
Employees32
International Stem Cell CORP competitors & alternatives →

Get AcroCyte Therapeutics's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

AcroCyte Therapeutics — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on AcroCyte Therapeutics in Xcout Intel

  • 5 named people with titles, LinkedIn and board committees
  • 1 funding round with the investors in each, and who they co-invest with
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →